Study of SHR-8068 with adebrelimab and chemo for lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new combination of drugs (SHR-8068 plus adebrelimab and chemotherapy) against another approved combination for people with advanced non-small cell lung cancer who have not had treatment yet. The goal is to see which combination works better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been newly diagnosed with advanced or spreading non-small cell lung cancer and have not had any treatment for it yet.
- Your lung cancer cannot be removed by surgery or cured with radiation and chemo together.
- You have a tumor sample that can be tested for PD-L1 (a protein that helps decide if immunotherapy could work).
- You are able to take care of yourself (ECOG score 0 or 1) and expected to live at least 3 months.
- You have at least one tumor that can be measured on a scan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, SHR-A2102 and Adebrelimab, with or without other treatments, for people with advanced or metastatic non-small cell lung cancer that cannot be removed by surgery or cured with radiation. It aims to see if this approach can shrink tumors or slow the cancer's growth.
This trial tests a new combination of drugs (an immunotherapy and a possible new treatment) plus chemotherapy for people with advanced lung cancer. The goal is to see if this combination can shrink tumors or stop them from growing.
This trial tests an investigational drug called SHR-1826 for people with non-small cell lung cancer that has spread or cannot be removed by surgery. It aims to see if the drug can shrink tumors and improve outcomes.
This trial tests two new drugs—SHR-A1921 and adebrelimab—for people with advanced non-small cell lung cancer (NSCLC) whose cancer has grown after standard first-line treatment. The goal is to see if this combination can help shrink tumors or slow cancer growth.
This trial tests a new drug combined with other treatments for people with lung cancer that can be removed by surgery. It aims to see if the treatment shrinks tumors before surgery and improves outcomes.
This trial tests a new drug combination for people with non-small cell lung cancer that has spread or cannot be removed by surgery. It aims to see if adding SHR2554 tablets to other anticancer treatments can help control the disease.
Hear when a new Advanced or Metastatic Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.